Burden of illness in Parkinson's disease

被引:238
作者
Huse, DM
Schulman, K
Orsini, L
Castelli-Haley, J
Kennedy, S
Lenhart, G
机构
[1] Thomson Medstat, Cambridge, MA 02140 USA
[2] Teva Neurosci, Kansas City, MO USA
关键词
Parkinson's disease; health economics; cost of illness; resource use;
D O I
10.1002/mds.20609
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This Study quantifies direct medical care costs for individual patients with Parkinson's disease (PD) and projects total national costs of PD. Anonymous, patient-level data on health care utilization and cost were obtained from Medstat's MarketScan Research Databases. Patients were selected for study if they had either two instances of a diagnosis of PD or one diagnosis and two or more prescriptions for PD-related medication. A control group of persons without PD was selected for comparison. Total annual health care utilization and costs were calculated for both PD patients and controls. A total of 20,016 patients with PD were identified and followed up for an average of 853 days. The mean age of the patients was 73.6 years. and 51.2% were women. Total annual direct costs were $23,101 (SD 27,529) per patient with PD versus $11,247 (SD 16,486) for controls. The regression-adjusted incremental direct cost of PD versus control was $10,349 (95% confidence interval, 9,053, 11,645). Adding $25,326 in indirect costs, and multiplying by 645,000 cases of PD in the United States, the total cost to the nation is projected to be $23 billion annually. This estimate is higher than most previous studies, with important implications for health care delivery systems worldwide. (c) 2005 Movement Disorder Society.
引用
收藏
页码:1449 / 1454
页数:6
相关论文
共 21 条
[1]   PROTEINURIA - CHANGES AND MECHANISMS IN TOXIC NEPHROPATHIES [J].
BERNARD, A ;
LAUWERYS, RR .
CRITICAL REVIEWS IN TOXICOLOGY, 1991, 21 (05) :373-405
[2]   Effectiveness and cost-benefit of influenza vaccination of healthy working adults - A randomized controlled trial [J].
Bridges, CB ;
Thompson, WW ;
Meltzer, MI ;
Reeve, GR ;
Talamonti, WJ ;
Cox, NJ ;
Lilac, HA ;
Hall, H ;
Klimov, A ;
Fukuda, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (13) :1655-1663
[3]  
*BUR CENS, CURR POP SURV
[4]  
Bureau of Labor Statistics, CONS PRIC IND
[5]  
Bureau of Labor Statistics, CURR EMPL STAT
[6]   The impact of treatment-resistant depression on health care utilization and costs [J].
Crown, WH ;
Finkelstein, S ;
Berndt, ER ;
Ling, D ;
Poret, AW ;
Rush, AJ ;
Russell, JM .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (11) :963-971
[7]   Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON collaborative study [J].
deRijk, MC ;
Tzourio, C ;
Breteler, MMB ;
Dartigues, JF ;
Amaducci, L ;
LopezPousa, S ;
ManubensBertran, JM ;
Alperovitch, A ;
Rocca, WA .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (01) :10-15
[8]   The economic impact of Parkinson's disease - An estimation based on a 3-month prospective analysis [J].
Dodel, RC ;
Singer, M ;
Kohne-Volland, R ;
Szucs, T ;
Rathay, B ;
Scholz, E ;
Oertel, WH .
PHARMACOECONOMICS, 1998, 14 (03) :299-312
[9]   Direct economic impact of Parkinson's disease: A research survey in the United Kingdom [J].
Findley, L ;
Aujla, M ;
Bain, PG ;
Baker, M ;
Beech, C ;
Bowman, C ;
Holmes, J ;
Kingdom, WK ;
MacMahon, DG ;
Peto, V ;
Playfer, JR .
MOVEMENT DISORDERS, 2003, 18 (10) :1139-1145
[10]   Burden of parkinsonism: A population-based study [J].
Guttman, M ;
Slaughter, PM ;
Theriault, ME ;
DeDoer, DP ;
Naylor, CD .
MOVEMENT DISORDERS, 2003, 18 (03) :313-319